Recent updates to clinical care for patients with ER-positive disease include the emergence of breast cancer subtypes, oral selective estrogen receptor degraders, and other oral targeted therapies.
Tony Berberabe, MPH
Tony Berberabe, MPH, is the Editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey.
Articles by Tony Berberabe, MPH
Circulating tumor DNA has improved risk stratification, increased minimal residual disease in patients with early-stage gastrointestinal cancers.
Radionuclides, such as radium-223 dichloride and lutetium Lu 177 vipivotide tetraxetan, now have an added overall survival benefit in metastatic castrate-resistant prostate cancer.
Findings from phase 3 adjuvant immuno-oncology trials in renal cell carcinoma have demonstrated some benefit in disease-free survival, but questions about overall survival remain.
The SINTRA-REV trial showed lower risk of transfusion dependency in patients with MDS treated with lenalidomide.
Results from the VERITAC trial presented at the 2022 San Antonio Breast Cancer Symposium showed that ARV-471 monotherapy may be active in ER-positive/HER2-negative locally advanced/metastatic breast cancer.
Refining current regimens and other emerging approaches will be delineated in melanoma, according to Omid Hamid, MD.
Although HER2 mutations present in many solid tumors, lung cancer is of particular interest because a significant number of mutations are found in the tyrosine kinase domain of the gene. Of those, about 90% take the form of insertions or deletions, according study findings.
Updated findings from the TRIDENT-1 suggest that repotrectinib could represent a potential new treatment option for patients with ROS1- positive advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.
Real-world research show the tolerability and effectiveness of trifluridine and tipiracil combined with bevacizumab for the treatment of patients with refractory metastatic colorectal cancer.
In an interview , Ali Zaidi, MD, discussed how the treatment landscape for patients with esophageal cancer has evolved over previous years and what research aims to look at in the near future.
A 5-year survival update of CheckMate 227 support the use of nivolumab plus ipilimumab in patients with advanced non–small cell lung cancer.
Although there have been major advances in treating CLL, the disease remains incurable in most cases, so there is room for improvement,
Investigators recommend that genomic testing be adopted to be a reflexive and natural step in evaluating patients with non–small cell lung cancer and colorectal cancer/
As the brentuximab vedotin plus AVD combination gains widespread use, clinicians should recognize the toxicities, such as the risk of neutropenic fever or peripheral neuropathy, according to Alison Moskowitz, MD.
Novel targets continue to emerge through clinical trials in peripheral T0cell lymphoma, in particular EZH 1 and EZH 2 inhibitors, which have strong single-agent efficacy.
Haris Ali, MD, explored the potential role of disease-modifying agents on transplant indications in this setting during the 10th Annual Meeting of the Society of Hematologic Oncology
Jennifer R. Brown, MD, PhD, understands that the goal for patients with cancer requires the highest standards of care, but delivering on that goal is a complicated clinical challenge.
Lionel Adès, MD, PhD, discussed emerging targeted therapies for myelodysplastic syndromes during a presentation at the 10th Annual Meeting of the Society of Hematologic Oncology.
Just as we were getting used to attending conferences via virtual platforms, SOHO 2022 kicks off as an in-person meeting.
Tyrosine kinase inhibitors now enjoy frontline approval, yet the role of interferon continues to be explored.
In LINKER-MM1 study, responses to REGN5458 occurred early, were durable, and deepened over time.
Although PD-L1 expression has limitations as a predictive biomarker, it has nonetheless driven clinical decision-making.
In the SIENDO clinical trials, selinexor show progression-free survival benefit in patients with select endometrial cancer subtypes.
Ajai Chari, MD, explains oncologists should expect from the upcoming 40th Annual CFS Innovative Therapy for Tomorrow.
A presentation by Richard S. Finn, MD, during the American Association for Cancer Research Special Conference, focused on phase 3 combination studies in that setting.
The superiority of the combination regimens for hepatocellular carcinoma treatment was demonstrated in results from the IMbrave150 and HIMALAYA trials, according to Josep M. Llovet, MD, PhD.
Findings from the ALCHEMIST trial indicate 53% of patients received adequate lymph node dissection and only 57% received adjuvant chemotherapy, despite indications for this treatment.
The phase 3 PADA-1 trial revealed a correlation between estrogen receptor- and progesterone receptor-positive metastatic breast cancer and prolonged progression-free survival.